FNAM 0.65 Evolutionary Genomics, Inc.
| Range: | 8.0E-4-0.45 | Vol Avg: | 247 | Last Div: | 0 | Changes: | -0.6 |
| Beta: | 0.07 | Cap: | 0.00B | Currency: | USD | Exchange: | OTC |
| Sector: | Healthcare | IPO: | Tue May 15 2012 | Empoloyees: | 2 | ||
| CUSIP: | 30051F101 | CIK: | 0000884363 | ISIN: | US30051F1012 | Country: | US |
| CEO: | Mr. Steve B. Warnecke | Website: | https://www.evolgen.com | ||||
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow